About Parallel Bio
Parallel Bio is a company based in Cambridge (United States) founded in 2020. Parallel Bio has raised $25.43 million across 3 funding rounds from investors including Refactor Capital, Y Combinator and AIX Ventures. The company has 6 employees as of December 31, 2022. Parallel Bio offers products and services including Immune Organoids Platform and AI Drug Discovery Service. Parallel Bio operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
- Headquarter Cambridge, United States
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Parallel Biosystems Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$25.43 M (USD)
in 3 rounds
-
Latest Funding Round
$21 M (USD), Series A
Jun 12, 2025
-
Investors
Refactor Capital
& 8 more
-
Employee Count
6
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Parallel Bio
Parallel Bio offers a comprehensive portfolio of products and services, including Immune Organoids Platform and AI Drug Discovery Service.
Enables in-vitro testing of drugs using human immune replicas.
Uses AI to analyze immune data for faster drug candidate verification.
People of Parallel Bio
Unlock access to complete
Funding Insights of Parallel Bio
Parallel Bio has successfully raised a total of $25.43M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Parallel Bio
Parallel Bio has secured backing from 9 investors, including venture fund and angel investors. Prominent investors backing the company include Refactor Capital, Y Combinator and AIX Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage investments are made across US and India.
|
Locked | Locked | Locked | |
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Venture capital is provided to AI-powered companies by AIX Ventures.
|
Locked | Locked | Locked |
Investor details for Parallel Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Parallel Bio
Investment portfolio details for Parallel Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Parallel Bio
Detailed financials for Parallel Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Parallel Bio Comparisons
Peer comparison for Parallel Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Parallel Bio
Parallel Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Developer of AI-based platform for lab-grown human tissues
|
|
| Locked | Locked | Locked |
Provider of computational tools for bacterial metabolomic and genomic data analysis
|
|
| Locked | Locked | Locked |
Scalable processes for organoid expansion are developed.
|
Detailed competitors of Parallel Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Parallel Bio
Complete news archive for Parallel Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Parallel Bio
Parallel Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Parallel Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Parallel Bio is a funded company, having raised a total of $25.43M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Parallel Bio is 6.
Parallel Bio was founded in 2020 and is located in Cambridge, United States. The companys domain, parallel.bio, serves as its primary online identifier. Limited details are available concerning its industry sector, specific operations, or services provided. Further information on core activities remains undisclosed in public sources at this time.
Parallel Bio's top competitors include Newcells Biotech, InSphero and Vivodyne.
Parallel Bio offers Immune Organoids Platform and AI Drug Discovery Service.
Parallel Bio has 9 investors. Key investors include Refactor Capital, Y Combinator, AIX Ventures, Marc Benioff, and Metaplanet.